Fortuitously, this article popped up in the literature.
Using mathematical modeling the authors simulated 3 strategies: (1) no allergy evaluation, treat with vancomycin (2) allergy history-guided treatment: if history excludes anaphylactic features treat with cefazolin and (3) complete allergy evaluation with history-appropriate PCN skin testing: if skin test negative, treat with cefazolin . Model outcomes included 12-week MSSA cure, recurrence, and death; allergic reactions and adverse drug reactions.
The use of vancomycin results in the fewest patients achieving MSSA cure and
the highest rate of recurrence. In brief- vancomycin yields the poorest
outcomes. The exclusion of a true allergy either by history or skin testing is preferred over simply prescribing vancomycin for MSSA bacteremia.
At the very least, when managing invasive staphylococcal infections, when informed of a penicillin allergy, this should be further addressed and not simply accepted as true as it impacts both choice of therapy outcome. It all comes back to taking a good history, as were taught in Practice of Medicine 101.